Publications

Vogl UM, Merler S, Angrisani A, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small EJ, Smith MR, Sweeney CJ, Tombal B, Zilli T, Herrmann K, Omlin A, Gillessen S, APCCC 2024 expert panel. A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024. European journal of cancer (Oxford, England : 1990). 2025. PMID: 41407614

Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer. 2025. PMID: 41271741

Celsa C, Pressiani T, Nishida N, Chamseddine SM, Arvind A, Li M, Fortuny M, Khaled NB, Iavarone M, Toyoda H, Rapposelli IG, Casadei-Gardini A, Vivaldi C, Ulahannan S, Andanamala H, Scheiner B, Pinter M, Orlandi E, Fulgenzi CAM, Manfredi GF, Lombardi P, D'Alessio A, Stefanini B, Villani R, Ponziani FR, Stella L, Carminati O, Ricci AD, Gonzalez M, Sparacino A, Di Maria G, Vaccaro M, Cabibbo G, Cammà C, Reig M, Kelley RK, Singal AG, Kaseb AO, Kudo M, Rimassa L, Pinato DJ. Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study. JHEP reports : innovation in hepatology. 2025. PMID: 41675370

Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O'Leary PC, Taha TY, Matsui Y, Zapatero-Belinchón FJ, McCavitt-Malvido M, Doruk YU, Stevens MGV, Diolaiti ME, Jogalekar MP, Chen H, Richards AL, Kongpracha P, Bali S, Montano M, Rosecrans J, Matthay M, Togo T, Gonciarz RL, Gopalkrishnan S, Neitz RJ, Krogan NJ, Swaney DL, Shoichet BK, Ott M, Renslo AR, Ashworth A, Fraser JS. The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2. eLife. 2025. PMID: 41258893

Lin Z, Ngo W, Chou YT, Wu H, Susa KJ, Jun YW, Bivona TG, Doudna JA, Wells JA. Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap. Nature chemical biology. 2025. PMID: 41254216

Lin C, Hadfield MJ, Santopietro A, Lagos G, Cheng L, El-Deiry WS, Aggarwal R, Mega A, Hyams E, Carneiro BA. The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. NPJ precision oncology. 2025. PMID: 41238753

Mulima G, Mody GN, Kaimila B, Salima A, Williams B, Paciorek A, Zhang L, Charles A, Westmoreland KD, Van Loon K, Buckle GC. Treatment Outcomes of Esophageal Cancer in Malawi: An Analysis of Overall Survival and Patient-Reported Outcomes. JCO global oncology. 2025. PMID: 41232057

Du J, Wijayaratna UN, Wang X, Fung JP, Huang B, Farzaneh F, Kohn DB, Combes AJ, Gaensler KML. TriLeukeVax: A CD80/IL-15/IL-15Rα Expressing Autologous AML Cell Vaccine Elicits Robust Anti-Leukemic Cytolytic Activity. bioRxiv : the preprint server for biology. 2025. PMID: 41279544

Tolaney SM, Sonpavde GP, Tarantino P, Lustberg MB, Rugo HS. Clinical perspective on management of key adverse events with sacituzumab govitecan. The oncologist. 2025. PMID: 41006069

Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O. Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. The oncologist. 2025. PMID: 41056445

Panian J, Henderson NC, Herchenhorn D, Barata PC, Bilen MA, Graham L, Heath E, Hwang C, Supernois A, Kilari D, Thapa B, Koshkin VS, Jindal T, Nauseef JT, Sokolova A, Amery T, Zakharia Y, Schweizer MT, Raychaudhuri R, Reichert ZR, Dorff T, Armstrong AJ, Wang J, Alva A, McKay RR. Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617. The oncologist. 2025. PMID: 41124032

Li Y, Qiu X, Sandusky Z, Tagliaferri K, Li R, Yang X, Zhang T, Liu S, Yan P, Lu F, Jones M, Xiao T, Li W, Goldman S, Cui J, Polyak K, Liu XS, Long HW, Gregory RI, Adelman K, Rosenbluth JM, Brown M. METTL3-dependent m6A RNA methylation suppresses aberrant mammary epithelial differentiation and neoplastic transformation. Proceedings of the National Academy of Sciences of the United States of America. 2025. PMID: 41218124

Abrams RPM, Donahue RG, Ma J, Mao Y, Diolaiti ME, Ashworth A. An engineered cysteine sensor optimized for high-throughput screening identifies regulators of intracellular thiol levels. Cell chemical biology. 2025. PMID: 41218609

Gujar R, Cui C, Fumagalli M, Martinez N, Bahador A, Algazi A, Harrington K, Turner C, Becker L. Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. Cell reports. Medicine. 2025. PMID: 41205593

Smabers LP, Nienhuis HH, de Leng WWJ, Roepman P, Ciftcibasi IÖA, Wensink GE, Huismans MA, Valkenburg-van Iersel LBJ, Cirkel GA, Gootjes EC, Verheul HMW, Jeurissen FJ, Bol GM, Kranenburg O, Koopman M, Cuppen E, Roodhart JML. Clinical implications of whole genome sequencing in metastatic colorectal cancer. Oncogene. 2025. PMID: 41203868

Zwart K, van Kruijsdijk RCM, Angerilli V, Baas MC, Dekker E, Rutgers N, May A, Koopman M, Nagtegaal ID, Bol GM. Risk of deficient mismatch repair colorectal cancer and precursors after kidney transplantation: A nationwide study. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2025. PMID: 41207478

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy. Haematologica. 2025. PMID: 41195510

Singal AG, Garcia-Reyes K, Kelley RK, Kim E. Impact of LEAP-012 and EMERALD-1 in the management of HCC. JHEP reports : innovation in hepatology. 2025. PMID: 41503570

Li H, Melnyk JE, Fu BXH, Shrestha R, Zhang M, Sjöström M, Feng S, Anderson JA, Han W, Chesner LN, Shin HJ, Farsh T, Suarez HJ, Nath S, Chou J, Das R, Egusa EA, Calvert M, Kishishita A, Barpanda A, Zhu J, Maheshwari A, Chen WS, Alshalalfa M, Winters A, Hua JT, Liu T, Davicioni E, Wiita AP, Stohr BA, Siddiqui J, Huang B, Small EJ, Shokat KM, Nelson PS, Quigley DA, Wasmuth EV, Gilbert LA, Feng FY. Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer. Nature genetics. 2025. PMID: 41193657

Ho C, Kennedy N, Di M, Gopal AK, Lynch RC, Ng K, Wu QV, Poh C, Raghunathan V, Rasmussen H, Shadman M, Till BG, Ujjani CS, Smith SD. Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2025. PMID: 41285650